FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655405> ?p ?o ?g. }

• W4385655405 endingPage "e949174e" @default.
• W4385655405 startingPage "e949174e" @default.
• W4385655405 abstract "Topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical Background: The treatment paradigms for B-cell malignancies including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are rapidly evolving. Fortunately, treatment options for CLL and MCL have expanded considerably in recent years thanks to an improved understanding of the molecular mechanisms underlying this disease. Bruton tyrosine kinase (BTK) inhibitors are one such treatment option. Although BTK inhibitors bring new hope to patients with CLL and MCL, the rapid introduction of these agents has also increased the complexity of treatment, making it challenging for hematologist/oncologists to incorporate these novel therapies into clinical practice. Given how quickly the use of BTK inhibitors in CLL and MCL treatment is evolving, it is difficult for even the most conscientious healthcare providers to stay up to date on advances. Aims: The aim of this study was to determine whether a comprehensive continuing medical education (CME) online curriculum could improve hematologist/oncologists’ knowledge, competence, and confidence in managing therapy for CLL and MCL with BTK inhibitors. Methods: The educational analysis consisted of 6 online, CME-certified activities. Educational impact was assessed with repeated pre-/post-education including multiple choice knowledge/competence questions and 5-point Likert scale confidence questions. Data from hematologists/oncologists who completed pre- and/or post-education assessments were analyzed. Absolute changes in percentage of correct responses and clinicians who were confident (value of 4 or 5) were used to measure improvement in knowledge, competence, and confidence. A McNemar’s test assessed significant levels of changes reported with P values <.05 considered statistically significant. The activities in this series launched January 4, 2022 through December 29, 2022, with each activity being available to learners for 1-year from launch date; data were collected through February 2023. Results: Multiple questions were used to aggregate data by theme across the 6 activities (n ranged from 30-365). Overall improvements in absolute change in knowledge/competence by learning theme were observed (Table 1). Hematologist/oncologists demonstrated statistically significant improvements in knowledge/competence related to clinical trial data on BTK inhibitors, treatment selection considerations for BTK inhibitors, real-world evidence on the use of BTK inhibitors, and mechanistic differences between BTK inhibitors. 87% of hematologist/oncologists experienced an improvement in or reinforcement of knowledge/competence from CME, which translated to significant improvements in confidence in treating patients with CLL and MCL using the latest evidence-base on BTK inhibitors after education (P<.001). Summary/Conclusion: An online curriculum-based approach was successful in improving knowledge, competence, and confidence of hematologist/oncologists’ ability to personalize care with BTK inhibitors for patients with B-cell malignancies. These results show the ability of education to translate to improvements in clinical care for patients with CLL and MCL. Continued curricula-based education can serve as a comprehensive means to further increase clinicians’ abilities in this clinical setting and optimize patient outcomes.Keywords: Mantle cell lymphoma, Chronic lymphocytic leukemia" @default.
• W4385655405 created "2023-08-09" @default.
• W4385655405 creator A5031072430 @default.
• W4385655405 creator A5034220290 @default.
• W4385655405 creator A5045572486 @default.
• W4385655405 date "2023-08-01" @default.
• W4385655405 modified "2023-09-26" @default.
• W4385655405 title "PB1943: THE EFFECTS OF AN ONLINE CURRICULUM BASED APPROACH TO CME ON HEMATOLOGIST/ONCOLOGISTS’ ABILITY TO TREAT PATIENTS WITH BTK INHIBITORS FOR B-CELL MALIGNANCIES" @default.
• W4385655405 doi "https://doi.org/10.1097/01.hs9.0000974588.94917.4e" @default.
• W4385655405 hasPublicationYear "2023" @default.
• W4385655405 type Work @default.
• W4385655405 citedByCount "0" @default.
• W4385655405 crossrefType "journal-article" @default.
• W4385655405 hasAuthorship W4385655405A5031072430 @default.
• W4385655405 hasAuthorship W4385655405A5034220290 @default.
• W4385655405 hasAuthorship W4385655405A5045572486 @default.
• W4385655405 hasBestOaLocation W43856554051 @default.
• W4385655405 hasConcept C100521375 @default.
• W4385655405 hasConcept C126322002 @default.
• W4385655405 hasConcept C143998085 @default.
• W4385655405 hasConcept C15744967 @default.
• W4385655405 hasConcept C170493617 @default.
• W4385655405 hasConcept C2777938653 @default.
• W4385655405 hasConcept C2778461978 @default.
• W4385655405 hasConcept C2779134260 @default.
• W4385655405 hasConcept C2779878957 @default.
• W4385655405 hasConcept C2908580079 @default.
• W4385655405 hasConcept C42362537 @default.
• W4385655405 hasConcept C71924100 @default.
• W4385655405 hasConcept C77805123 @default.
• W4385655405 hasConcept C90059517 @default.
• W4385655405 hasConceptScore W4385655405C100521375 @default.
• W4385655405 hasConceptScore W4385655405C126322002 @default.
• W4385655405 hasConceptScore W4385655405C143998085 @default.
• W4385655405 hasConceptScore W4385655405C15744967 @default.
• W4385655405 hasConceptScore W4385655405C170493617 @default.
• W4385655405 hasConceptScore W4385655405C2777938653 @default.
• W4385655405 hasConceptScore W4385655405C2778461978 @default.
• W4385655405 hasConceptScore W4385655405C2779134260 @default.
• W4385655405 hasConceptScore W4385655405C2779878957 @default.
• W4385655405 hasConceptScore W4385655405C2908580079 @default.
• W4385655405 hasConceptScore W4385655405C42362537 @default.
• W4385655405 hasConceptScore W4385655405C71924100 @default.
• W4385655405 hasConceptScore W4385655405C77805123 @default.
• W4385655405 hasConceptScore W4385655405C90059517 @default.
• W4385655405 hasIssue "S3" @default.
• W4385655405 hasLocation W43856554051 @default.
• W4385655405 hasLocation W43856554052 @default.
• W4385655405 hasOpenAccess W4385655405 @default.
• W4385655405 hasPrimaryLocation W43856554051 @default.
• W4385655405 hasRelatedWork W2035536649 @default.
• W4385655405 hasRelatedWork W2071549499 @default.
• W4385655405 hasRelatedWork W2226560286 @default.
• W4385655405 hasRelatedWork W2316021978 @default.
• W4385655405 hasRelatedWork W2417539529 @default.
• W4385655405 hasRelatedWork W2529033697 @default.
• W4385655405 hasRelatedWork W4210347204 @default.
• W4385655405 hasRelatedWork W4225515604 @default.
• W4385655405 hasRelatedWork W4286270432 @default.
• W4385655405 hasRelatedWork W4377088465 @default.
• W4385655405 hasVolume "7" @default.
• W4385655405 isParatext "false" @default.
• W4385655405 isRetracted "false" @default.
• W4385655405 workType "article" @default.